IL27 and pachyonychia congenita: Bioinformatics and immunopathological studies on clinical samples from independent cohorts of PC patients underline the translational value of the experimental findings and highlight the antiangiogenic implication of a therapeutic, tumor selective, IL30 inhibition to fight PC progression.